Tyverb is indicated, in combination with Herceptin, for the treatment of adult patients with breast cancer whose tumours overexpress HER2


The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product Tyverb ( Lapatinib ).

Tyverb is indicated for the treatment of adult patients with breast cancer whose tumours overexpress HER2 ( ErbB2 ) in combination with Capecitabine or an aromatase inhibitor. The CHMP has now recommended it for the treatment in combination with Trastuzumab ( Herceptin ).

The full indication for Tyverb will now be as follows:  Tyverb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress HER2 ( ErbB2 );

a) in combination with Capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with Trastuzumab in the metastatic setting.

b) in combination with Trastuzumab for patients with hormone receptor-negative metastatic disease that has progressed on prior Trastuzumab therapy(ies) in combination with chemotherapy;

c) in combination with an aromatase inhibitor for postmenopausal women with hormone receptor positive metastatic disease, not currently intended for chemotherapy. The patients in the registration study were not previously treated with Trastuzumab or an aromatase inhibitor. No data are available on the efficacy of this combination relative to Trastuzumab in combination with an aromatase inhibitor in this patient population. ( Xagena )

Source: European Medicines Agency ( EMA ), 2013

XagenaMedicine_2013



Indietro

Altri articoli

HER2 targeted therapies have substantially improved the prognosis of patients with breast cancer however they can be associated with cardiac...


Investigational hunter immune cells engineered to seek out and attack a deadly brain cancer known as glioblastoma ( GBM )...


Compared with traditional chemotherapy, targeted cancer therapy is a novel strategy in which key molecules in signaling pathways involved in...


Approximately a quarter of women with HER2 positive breast cancer, who were treated with a combination of the targeted drugs...


Among patients with HER2-positive, metastatic breast cancer that had progressed despite treatment with two or more forms of HER2-targeted therapy...


PIK3CA mutations are common in breast cancer. The aim of a study was to evaluate the correlation of PIK3CA mutational...


The CHER-LOB randomized phase II study showed that the combination of Lapatinib ( Tyverb ) and Trastuzumab ( Herceptin )...


Results from the phase III clinical trial of the investigational drug PB272 ( Neratinib ) for the extended adjuvant treatment...


In the randomised, controlled, phase 3 trial NeOAdjuvant Herceptin ( NOAH ) trial in women with HER2-positive locally advanced or...


Disease progression in patients with HER2-positive breast cancer receiving Trastuzumab ( Herceptin ) might be associated with activation of the...